Please be kindly invited to join us to this webinar.
MBD Co., Ltd. from South Korea (Medical & Bio Decision) will present on Thursday, January 15, 9 am its solution for an automated, cell-level 3D organoid-based
high-throughput screening (HTS) process for efficacy and toxicity testing.
The company has developed a new 3D cell culture technology that enables the cultivation of organoids and the automated, high-throughput analysis and evaluation of drug or anticancer compound efficacy
and toxicity. This platform addresses the key challenges in conventional organoid research — reproducibility, standardization, and throughput — significantly improving the efficiency and accuracy of preclinical and clinical studies for new drug development.
Based on this platform, MBD currently collaborates with
over 30 university hospitals in Korea as well as several research institutes in Europe, offering personalized chemotherapy efficacy testing services.
MBD would be interested in a collaboration with University of Oulu research groups. Different kinds of funding possibilites, e.g. EU funding and perhaps funding from the Academy of Finland could
be considered for a common research project.
Dr. Ulla Lenkkeri-Schütz with SkyinQ Team from Luxembourg will be hosting the event.
|
|